Moderna mRNA Flu Vaccine Approved for Adults 50+

Moderna said the US Food and Drug Administration has approved its influenza vaccine mFlusiva, marking the first flu shot for older adults made using an mRNA platform. The company said the vaccine is intended for adults aged 50 or older.

According to Moderna, mFlusiva uses the same mRNA approach that became central during the Covid-19 pandemic. The company framed the approval as a new application of that technology in seasonal vaccination.

FDA decision and who the vaccine is for Moderna said the authorization covers use in people 50 and above. The company did not describe additional eligibility details in its announcement as provided.

The approval arrives as pharmacies prepare for the fall vaccination period. Moderna noted that other flu vaccine brands have already started reaching pharmacy channels ahead of the seasonal rollout.

Availability timeline and retail rollout

Moderna said late on Wednesday that it expects some doses of mFlusiva to be available soon at select retailers. The company did not specify which retailers or provide quantities in the information released.

Seasonal influenza vaccination typically ramps up in the months leading into autumn, with multiple manufacturers supplying shots through pharmacy and clinical settings. Moderna’s statement positioned mFlusiva as an additional option within that established distribution cycle, rather than a replacement for existing products.

mRNA platform expands beyond Covid-19

The company’s announcement linked the flu vaccine to the broader mRNA platform that was widely deployed during the Covid-19 pandemic. Moderna described that platform as key to ending the coronavirus pandemic.

Beyond Moderna’s specific product, the FDA decision underscores that mRNA-based vaccines are being used for more than pandemic response, extending into routine immunization categories such as influenza for older adults. The company did not provide further technical or comparative details in the source material.

What remains unclear from the announcement

Moderna did not disclose in the provided information how many doses would be available initially, how quickly distribution might broaden beyond select retailers, or whether additional regulatory filings are planned for other age groups.

For consumers, timing may depend on local pharmacy inventory and appointment availability as the fall season approaches. Moderna’s statement indicated only that limited availability is expected soon.